Biomarkers Market Size, Share & Trends Report

Biomarkers Market Size, Share & Trends Analysis Report By Type (Safety, Efficacy, Validation), By Application (Diagnostic, Drug Development, Personalized Medicine), By Disease, And Segment Forecasts, 2019 - 2026

  • Published Date: Apr, 2019
  • Base Year for Estimate: 2018
  • Report ID: 978-1-68038-979-1
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2017
  • Number of Pages: 103

Industry Insights

The global biomarkers market size was valued at USD 40.8 billion in 2018 and is expected to expand at a CAGR of 14.2% over the forecast period. Technological advancements in development of biomarker-based diagnostics are likely to contribute to the expansion of the market.

Increase in global disease burden, especially with high prevalence of cancer, diabetes, cardiovascular disorders, and other chronic diseases supported by unhealthy diet, lack of exercise, and a sedentary lifestyle, has been a major factor driving the market growth. According to the World Health Organization (WHO), the aforementioned diseases accounted for more than 50% of 56.9 million deaths globally, in 2016.

U.S. biomarkers market

Technological advancements have made it possible to combine biomarkers with novel drugs for accurate diagnosis and improved treatment. For instance, biomarkers are used for the treatment of neurological diseases by tracking brain health through measurement of biomolecules. Recent developments, such as biomarker signatures, are making neurological diseases more treatable resulting in non-invasive testing, faster drug development, and early diagnosis.

The introduction of Clinical Laboratory Improvement Amendments (CLIA) waived tests for biomarkers is expected to significantly drive market growth. Government initiatives aimed at reducing healthcare expenses via personalized medicines in an attempt to focus on prevention and early detection of diseases is further anticipated to propel growth.

Type Insights

Safety biomarkers led the type segment in 2018, driven by increasing adoption in drug discovery and development. Safety biomarkers are applied in preclinical trials to select drug candidates likely to be well-tolerated by humans, which thereby reduces the time and cost required for preclinical safety evaluation and drug development.

Validation biomarkers is anticipated to exhibit lucrative growth over the forecast period, fueled by their extensive usage in pharmaceutical companies. These biomarkers can predict therapeutic failure of drugs by identifying the non-responders with low therapeutic profile and distinct genetic profile.

Application Insights

Drug discovery segment held the largest market share in 2018, and is expected to continue leading through the forecast period. Biomarkers impact the decisions of many key players of whether to move to the next clinical development phase or not. Furthermore, pharmaceutical companies are undertaking extensive R&D initiatives to develop targeted therapeutics.

Personalized medicine is anticipated to witness lucrative growth over the forecast period, supported by high demand and consumer awareness. Moreover, increasing number of approvals for companion diagnostic tests for cancer drugs is expected to aid market growth.

Disease Insights

The cancer segment led the biomarkers market in 2018, driven by increasing demand for rapid and accurate diagnostic tools as well as rise in global incidence of cancer. Significant demand for personalized medicines and strategic collaborations between pharmaceutical and diagnostic companies is likely to drive the segment.

Germany biomarkers market

Cardiovascular disease is expected to be the fastest growing segment over the forecast period. Cardiovascular diseases are the leading cause of mortality and morbidity in U.S. Companies are currently focusing on identification of cardiac biomarkers as they provide increased understanding of the pathophysiology of such conditions. 

Regional Insights

North America led, by contributing more than 41.0% to the overall market share in terms of revenue in 2018, driven by rising disease burden and favorable government initiatives. Presence of regulatory entities as well as key manufacturers is expected to foster the growth of biomarker-based drug development in near future.

Asia Pacific is estimated to expand at a lucrative CAGR of over 16.0% during the forecast period. Some factors responsible for the growth are local presence of leading biomarker companies and increasing R&D investment in developing countries. Moreover, the cost of clinical trials in developing countries is lower than that in developed countries. This factor is anticipated to bode well for regional market growth.

Biomarkers Market Share Insights

Some key market players include F. Hoffmann-La Roche Ltd.; Abbott.; Agilent Technologies, Inc.; Epigenomics AG; Johnson & Johnson Services, Inc; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Siemens Healthcare Private Limited; and Qiagen.

Key players adopt various strategies such as mergers and acquisitions, new product developments, and initiatives to promote awareness to maintain their market share.  For instance, in May 2017, the U.S. Food and Drug Administration (FDA) approved Roche Diagnostics biomarker assay for bladder cancer. Biomarker assay test evaluates the status of patient PD-L1 by using both immune cell staining and tumor cell staining and scoring within the tumor.

Report Scope

Attribute

Details

Base year for estimation

2018

Actual estimates/Historical data

2014 - 2017

Forecast period

2019 - 2026

Market representation

Revenue in USD Million & CAGR from 2018 to 2026

Regional scope

North America, Europe, Asia Pacific, Latin America, MEA

Report coverage  

Revenue forecast, company share, competitive landscape, growth factors and trends

Country Scope

U.S., Canada, UK, Germany, France, China, India, Brazil, Mexico, South Africa

15% free customization scope (equivalent to 5 analysts working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global biomarkers market report on the basis of type, application, disease, and region:

  • Type Outlook (Revenue, USD Million, 2014 - 2026)

    • Safety

    • Efficacy

    • Validation

  • Application Outlook (Revenue, USD Million, 2014 - 2026)

    • Diagnostics

    • Drug discovery & development

    • Personalized medicines

    • Others

  • Disease Outlook (Revenue, USD Million, 2014 - 2026)

    • Cancer

    • Cardiovascular Diseases

    • Neurological Diseases

    • Immunological Diseases

    • Others

  • Regional Outlook (Revenue, USD Million, 2014 - 2026)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • Spain

      • France

      • Italy

    • Asia Pacific

      • India

      • China

      • Japan

      • South Korea

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified